Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY | News

Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY | News

The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians…

Continue Reading
FDA Approves First-in-Class Drug for Gastric Cancer

FDA Approves First-in-Class Drug for Gastric Cancer

The FDA has approved Vyloy (zolbetuximab-clzb) as a first-line treatment of adults with locally advanced unresectable…

Continue Reading
RNT Health Insights’ gastric cancer tool gets breakthrough device designation

RNT Health Insights’ gastric cancer tool gets breakthrough device designation

RNT Health Insights’ early gastric cancer detection tool has a 96% accuracy rate. Credit: SofikoS /…

Continue Reading
Astellas’ Vyloy combination approved by MHRA as first-line gastric cancer treatment

Astellas’ Vyloy combination approved by MHRA as first-line gastric cancer treatment

Astellas Pharma’s Vyloy (zolbetuximab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA)…

Continue Reading
Study reveals that gastric cancer surgery may reduce heart disease risk

Study reveals that gastric cancer surgery may reduce heart disease risk

The study reveals that gastrectomy reduced the incidence of MACE compared with the general population. The…

Continue Reading
IBI Healthcare Partners with Dr. Jeffrey Brooks, MD, Spatz Medical Adjustable Reversible Spatz3 Gastric Balloon

IBI Healthcare Partners with Dr. Jeffrey Brooks, MD, Spatz Medical Adjustable Reversible Spatz3 Gastric Balloon

IBI Healthcare Partners with Spatz Medical for Revolutionary Spatz3 Gastric Balloon. Enhancing Patient Outcomes with Innovative…

Continue Reading